Breaking News

Advinus Earns Takeda Milestone

By Kristin Brooks | January 7, 2014

R&D collaboration completes first successful year

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Co., has received a $3 million milestone for the first successful year in its R&D collaboration with Takeda Pharmaceutical Co.
 
In October 2012, the companies entered a multi-year, multi-project drug discovery collaboration. Advinus is responsible for carrying out all research required to identify candidate molecules for clinical development in several therapeutic areas, and Takeda is responsible for development and commercialization.
 
"Achievement of the rather challenging first year milestone can be attributed to the truly collaborative nature of our relationship with Takeda as well as Advinus' ability to solve complex problems with efficiency and speed,” said Kasim Mookhtiar, chief scientific officer of Advinus.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent